Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) launched Caris ChromoSeq on April 2, 2026: a combined Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay for myeloid malignancies.
The test delivers ~250x genome read depth, 40 million transcriptome reads, supports bone marrow or peripheral blood samples, and has an expected seven-day turnaround.
Positive
- Single-test profiling replaces multiple myeloid diagnostic assays
- 250x genomic read depth for enhanced variant detection
- 40 million transcriptome reads for greater RNA resolution
- Seven-day expected turnaround to accelerate clinical decisions
Negative
- Intended only for myeloid malignancies (AML, MDS, MPN) limiting addressable scope
- Requires bone marrow aspirate or peripheral blood samples for testing
Key Figures
Market Reality Check
Peers on Argus
CAI gained 6.99% while key biotech peers were mixed to negative (e.g., MRNA -3.12%, ROIV -1.03%, MDGL -0.28%), indicating a stock-specific reaction to the ChromoSeq launch rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Clinical study results | Positive | +7.0% | Final Achieve 1 data showing strong sensitivity and specificity for Caris Detect. |
| Mar 26 | AI product expansion | Positive | -1.2% | New AI Insights signatures for brain metastasis risk in breast and NSCLC. |
| Mar 25 | Conference presentations | Positive | -3.5% | Announcement of six oncology studies using proprietary multimodal data at AACR 2026. |
| Mar 24 | Diagnostic testing focus | Positive | -0.1% | Emphasis on DPYD testing integrated into Caris Assure blood-based sequencing assay. |
| Mar 20 | AI diagnostic study | Positive | -2.1% | GPSai study showing reclassification of misdiagnosed cancers and treatment changes. |
Recent news has been consistently positive on technology and data advances, yet the stock often showed negative next-day reactions, with only the Achieve 1 study producing a strong positive move.
Over the last weeks, Caris Life Sciences has highlighted multiple precision oncology advances. On Mar 20, a JAMA-published GPSai study showed reclassification of misdiagnosed cancers, but shares fell. Subsequent news on DPYD testing, AACR presentations, and new AI Insights for metastasis risk likewise saw modest to negative reactions. Only the Mar 31 Achieve 1 Caris Detect data aligned with a +6.99% move. Today’s ChromoSeq launch continues the theme of expanding whole genome and transcriptome-based diagnostics within a still-depressed share price versus the 52-week high $56.14.
Market Pulse Summary
This announcement expands Caris Life Sciences’ whole genome and whole transcriptome capabilities into myeloid malignancies, offering 250x genomic coverage, 40 million transcriptome reads, and a 7-day turnaround in a single assay. It builds on recent Caris Detect and GPSai studies and the company’s large multimodal datasets. Investors can watch how quickly ChromoSeq integrates into real-world workflows and how it contributes to utilization trends highlighted in prior clinical and AI-focused updates.
Key Terms
whole genome sequencing medical
acute myeloid leukemia medical
myelodysplastic syndromes medical
myeloproliferative neoplasms medical
peripheral blood medical
AI-generated analysis. Not financial advice.
Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight
Myeloid malignancies are among the most genetically complex cancers, often requiring multiple tests to identify clinically relevant mutations, structural variants and chromosomal abnormalities. This fragmented approach can delay critical treatment decisions and miss detection of important genomic alterations used for diagnosis and risk stratification.
Caris ChromoSeq can replace the multiple test protocols of the myeloid diagnostic workflow, complementing the clinician's overall clinical and pathological evaluation. Building on this foundation, the test delivers approximately 250x read depth across the genome with 40 million transcriptome reads, enabling enhanced genomic resolution from a bone marrow aspirate or peripheral blood collection. Results are synthesized into a single, easy‑to‑interpret, actionable report to support confident, timely clinical decision‑making, with an expected seven-day turnaround time.
"The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test. Never before have patients and physicians had access to a technology with the depth and breadth provided by Caris ChromoSeq," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. "This launch reflects our commitment to delivering a single, integrated genomic solution for patients with hematological cancers that fits into real‑world clinical workflows and provides results fast enough to inform patient care."
The launch of Caris ChromoSeq underscores Caris Life Sciences' ongoing focus on advancing precision medicine through innovative molecular profiling technologies that simplify complexity and support clinicians across the cancer care continuum.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-302732465.html
SOURCE Caris Life Sciences
FAQ
What is Caris ChromoSeq and which myeloid diseases does CAI target with it?
What sequencing depth and transcriptome coverage does Caris ChromoSeq (CAI) provide?
How fast are results from Caris ChromoSeq for investors considering CAI's clinical offerings?
Can Caris ChromoSeq replace existing myeloid diagnostic workflows for clinicians and CAI customers?
What specimen types are required for Caris ChromoSeq and are there sample limitations for CAI's assay?
